A Novel Strategy for Bespoke Tissue-Specific Biomarkers for Drug Development

Posted by

Technology Networks

Whilst enormous strides have been made in the discovery and verification of biomarkers for application in drug development, it is true to say that there is still no single integrated strategy that can deliver bespoke drug-specific/tissue-specific biomarkers of drug effect. Our objective is to identify specific pre-clinical tissue biomarkers of drug effect with surrogate (serum/plasma marker, urine) biomarkers obtained during clinical trials and the eventual development of clinical tools for the identification of drug efficacy and adverse events. This paper will describe how we are employing genomic, and proteomic technologies, in particular the integration of MALDI imaging and tissue microarrays, to deliver on tissue specificity and how this is intended to link through to surrogate serum markers of drug effect.